Skip to content

Reconstruction Outcomes in Immediate Post-mastectomy Breast Reconstruction With ADM

A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing Prosthetic, Acellular Dermal Matrix (ADM) Assisted, Immediate Post-Mastectomy Breast Reconstruction

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03145337
Enrollment
224
Registered
2017-05-09
Start date
2017-07-01
Completion date
2019-05-31
Last updated
2018-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Reconstruction

Brief summary

Evaluation and comparison of clinical and aesthetic outcomes associated with the use of two allograft dermal matrices (ADMs) currently in use for tissue assisted immediate post-mastectomy breast reconstruction.

Detailed description

This is a level one, prospective, randomized, controlled multi-center clinical study comparing two types of acellular dermal matrices (ADMs) currently used in immediate post-mastectomy prosthetic breast reconstruction. Comparison of these two ADMs will be made in the areas of reconstructive clinical outcomes and aesthetic outcomes. Patients will be randomized into one of two ADM groups as part of their immediate post-mastectomy breast reconstruction. Patients in both groups will be followed for twelve months after their reconstructive surgery. Clinical outcomes will be documented at 1 month, 3 months, 6 months and 12 months following breast reconstructive surgery. For one-stage breast reconstruction, aesthetic outcomes will be assessed and documented at 6 and 12 months following implant placement. For two-stage reconstruction, patients will be evaluated for aesthetic outcomes at a time point 6-12 months following expander-to-implant exchange if it does not coincide with the 12 month post-mastectomy visit.

Interventions

BIOLOGICALFlexHD ADM (Cohort A)

Tissue assisted breast reconstruction with FlexHD pliable perforated ADM

BIOLOGICALAlloDerm RTU ADM (Cohort B)

Tissue assisted breast reconstruction with AlloDerm RTU perforated ADM

Sponsors

Musculoskeletal Transplant Foundation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

3-4 independent breast surgeons using predefined criteria will assess the aesthetic outcomes of each subject using photographs of their pre-mastectomy and 12 month post-reconstructions. The surgeons will not be apprised of the ADM type or post-mastectomy site/surgeon

Intervention model description

Prospective, randomized, controlled

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Scheduled to undergo immediate, post-mastectomy, tissue assisted breast reconstruction, Reconstruction shall be either one-stage (direct-to-implant) or two-stage, unilateral or bilateral, prophylactic or therapeutic 2. Females at least 18 years of age 3. Non-smokers, former smokers and/or smokers who have not smoked within 1 month before surgery, and who agree to not smoke or utilize e-cigarettes during the post-operative period 4. Have signed a written informed consent 5. Have the ability to understand and comply with the requirements and follow-up time points of the study

Exclusion criteria

1. Previous breast surgery with the exception of biopsy 2. Previous radiation treatment in either breast at any time 3. Undergoing autologous breast reconstruction 4. Pre-pectoral implant placement 5. Undergoing delayed reconstruction 6. Requiring Wise pattern reduction of mastectomy skin flap 7. History of chronic steroid use within the past 6 months 8. History of HIV positive 9. Previous organ transplant 10. Pregnant or lactating females 11. Clinically significant systemic disease, as determined by the investigator, which could affect study participation or study results

Design outcomes

Primary

MeasureTime frameDescription
Post Reconstruction Complication Rates12 monthsTo compare the overall complication rate between the cohorts defined as either 1) post-operative infection specific to the reconstructed breast(s) requiring either intravenous antibiotic treatment or operative intervention, 2) seroma, and/or 3) reconstructive failure

Secondary

MeasureTime frameDescription
Comparison of Each Complication Rate12 monthsTo compare each complication rate between the cohorts defined as 1) post-operative infection specific to the reconstructed breast(s) requiring either intravenous antibiotic treatment or operative intervention 20 seroma 3) reconstructive failure and 4) reoperation for reasons other than infection
Comparison of Aesthetic Outcomes (Photographs)12 monthsA blinded comparison of aesthetic outcomes (photographs) using pre-defined criteria

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026